Indicated for stroke prevention and DVT to manage blood clotting and support cardiovascular safety.
Mechanism of Action
Dabigatran is a competitive, direct thrombin inhibitor. By blocking thrombin, it prevents the conversion of fibrinogen into fibrin, which inhibits the formation of blood clots without requiring routine blood monitoring.
Route of Administration
Oral
Onset Time
2 hours
Duration
12–17 hours (half-life)
Contraindications
Active pathological bleeding, Mechanical prosthetic heart valve, Severe renal impairment, Hypersensitivity to dabigatran
Severe Adverse Events
Major hemorrhage, Gastrointestinal perforation, Anaphylaxis — requires immediate medical attention
Information related to Pradaxa is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
